Drug intelligence / Profile preview

REGEND-010

Development stage: Preclinical
Lead developer: Regend Therapeutics
Modality: Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

REGEND-010 is a therapeutic vaccine in preclinical development, classified as a circular RNA (circRNA) vaccine. It is being developed by Regend Therapeutics for the treatment of neoplasms (cancers) and fibrosis. As a circRNA-based therapeutic vaccine, it likely works by encoding antigens or immunomodulatory molecules to stimulate an immune response against disease targets, though specific molecular targets and mechanisms have not been disclosed publicly. The drug's highest reported R&D status is preclinical, with active indications in neoplasms and fibrosis[1].

Beyond the preview

Go deeper on REGEND-010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGEND-010.

Explore the full profile